More Than Hair Loss: Current and Emerging Therapies for Alopecia AreataPremiere Date: Thursday, June 16, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, June 16, 2023
Note: Credit Is No Longer Available
|Nekma Meah, MBChB, MRCP (UK), MRCP (Derm), FACD
Honorary Secretary, British Hair and Nail Society
BMI The Beardwood Hospital
|Dmitri Wall, MB BCh BAO, MRCP (UK), MSc (Faculty)
Charles Institute of Dermatology
University College Dublin School of Medicine
Hair Restoration Blackrock
Current treatments for alopecia areata (AA) include topical and systemic anti-inflammatories, immunosuppressants, and immunosensitizers depending on patient age and disease severity. Because these therapeutic options produce variable clinical outcomes, each case must be approached on a customized, individual basis. A developing pipeline of immunomodulating agents (e.g. Janus kinase inhibitors) offers promise to bridge significant treatment gaps left by current therapies. It is important that clinicians who treat patients with AA elevate their knowledge of both current and emerging therapies for AA in order to enhance best practices and patient outcomes.
Join us for the third installment of this three-part virtual Journal Club series, More Than Hair Loss: Current and Emerging Therapies for Alopecia Areata, as Drs. Nekma Meah and Dmitri Wall explore the evolving landscape of AA treatment.
At the end of this CE activity, participants should be able to:
- Review current and emerging treatments for AA.
Supported by an educational grant from Pfizer Inc.
Physicians, PAs, and nurse practitioners specializing in dermatology, allergy/immunology, general practice, and/or pediatrics located outside of the United States
Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Radnor, Pennsylvania, USA. Please retain your certificate as proof of completion.
Through a mutual recognition agreement between the AMA and the DHP, physicians licensed in Qatar completing an activity from a US-based ACCME-accredited CME provider can use ACCME AMA PRA Category 1 Credits™ toward their credit requirements.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Dr. Meah reports no financial relationships.
Dr. Wall reports the following financial relationships:
Consultant: Bristol Myers Squibb and Pfizer Inc. (on behalf of the National and International Skin Registry)
Grants/Research Support: Janssen Global Services, LLC and Pfizer Inc.
Other: National and International Skin Registry Solutions (Charity)
The following peer reviewer and CME Outfitters staff report no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).